NL-OMON47219已完成不适用
Improving the tolerability of the oral targeted anti-cancer drug pazopanib by food intake (DIET). - DIET
Apotheek0 个研究点目标入组 97 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 97
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1) Subjects must provide written informed consent prior to performance of study-specific procedures or assessments and must be willing to comply with treatment and follow-up.
- •2) * 18 year old men and women who use pazopanib
- •3) Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
排除标准
- •1) Clinically significant gastrointestinal abnormalities that may affect absorption of investigational product including,
- •2) Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with subject*s safety, provision of informed consent, or compliance to study procedures.
- •3) Unable or unwilling to discontinue use of prohibited medications
- •4) Concurrent use of other substances known or likely to interfere with the pharmacokinetics of pazopanib.
研究者
相似试验
进行中（未招募）
1 期
To study the effect of food on the absorption of pazopanib and on the occurence of side effects when pazopanib is ingested with food.Patients who are treated or will be treated with pazopanib.MedDRA version: 19.0 Level: PT Classification code 10067946 Term: Renal cell carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0 Level: LLT Classification code 10073145 Term: Soft tissue cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-004108-20-NLRadboud University Nijmegen Medical Centre79
进行中（未招募）
2 期
Establishment of oral care method to reduce the number of bacteria in saliva of patients undergoing cancer surgeryJPRN-jRCT1071230048Soutome Sakiko60
进行中（未招募）
不适用
Efficacy and tolerability of a new oral extended-release formulation containing Low Molecular Weight Heparin (CB-01-05-MMX), administered as add-on therapy to oral mesalazine or other 5-ASA derivatives, in patients with active, left-sided, mild to moderate ulcerative colitis. A multicentre randomized, double-blind, comparative study versus placebo.Active left-sided, mild to moderate ulcerative colitisMedDRA version: 8.1Level: LLTClassification code 10045365Term: Ulcerative colitisEUCTR2006-001782-42-HUCosmo Technologies Ltd120
进行中（未招募）
1 期
Efficacy and tolerability of a new oral extended-release formulation containing Low Molecular Weight Heparin (CB-01-05-MMX), administered as add-on therapy to oral mesalazine or other 5-ASA derivatives, in patients with active, left-sided, mild to moderate ulcerative colitis. A multicentre randomized, double-blind, comparative study versus placebo.EUCTR2006-001782-42-GBCosmo Technologies Ltd120
进行中（未招募）
不适用
Efficacy and tolerability of a new oral extended-release formulation containing Low Molecular Weight Heparin CB-01-05-MMXTM , administered as add-on therapy to oral mesalazine or other 5-ASA derivatives, in patients with active, left-sided, mild to moderate ulcerative colitis. A multicentre randomized, double-blind, comparative study versus placebo. - NDEUCTR2006-001782-42-ITCOSMO TECHNOLOGIES LTD120